Physician profile
Rajesh Gupta
NPI 1902891393
$2,445.28
in general payments reported to CMS, 2019-2025
10 companies · $244 in 2025
The $244 reported for 2025 was more than what 86% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.35 · 2020: $393 · 2021: $643 · 2022: $626 · 2023: $81.62 · 2024: $411 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $736.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $1,471.35 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $371.04 | 2024-2025 | Tezspire, Breztri, Airsupra |
| Novo Nordisk INC | $227.85 | 2024-2025 | Wegovy |
| Glaxosmithkline, LLC. | $148.78 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $72.97 | 2021 | |
| Novartis Pharmaceuticals Corporation | $44.26 | 2023-2024 | |
| Paratek Pharmaceuticals, INC. | $39.94 | 2022-2024 | Nuzyra |
| Genentech USA, INC. | $37.02 | 2019-2020 | |
| Lilly USA, LLC | $16.06 | 2025 | Mounjaro |
| Edwards Lifesciences Corporation | $16.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.